Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Society, A.C. Survival rates for colorectal cancer. 2023 [cited 2023 March 4]; Available from: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html.

Siegel RL, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023.

Network, N.C.C. National Comprehensive Cancer Network. Colon Cancer (Version 2.2023). 2023. [cited 2023 May 16]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

Network., N.C.C. National Comprehensive Cancer Network. Rectal Cancer (Version 4.2022). 2022. [cited 2023 March 3]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.

Cervantes A, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

Article  CAS  PubMed  Google Scholar 

Nordlinger B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordlinger B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.

Article  CAS  PubMed  Google Scholar 

Venderbosch S, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antoniotti C, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7):876–87.

Article  CAS  PubMed  Google Scholar 

Elez E, Baraibar I. Immunotherapy in colorectal cancer: an unmet need deserving of change. Lancet Oncol. 2022;23(7):830–1.

Article  PubMed  Google Scholar 

Rossini D, et al. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): updated and overall survival results of the phase II randomized AtezoTRIBE study. J Clin Oncol. 2023;41(16_suppl):3500–3500.

Article  Google Scholar 

Antoniotti C, et al. An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Clin Cancer Res. 2023;29(12):2291–8.

Article  CAS  PubMed  Google Scholar 

Andreyev HJ, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90(9):675–84.

Article  CAS  PubMed  Google Scholar 

Andreyev HJ, et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer. 2001;85(5):692–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richman SD, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27(35):5931–7.

Article  CAS  PubMed  Google Scholar 

Bylsma LC, et al. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis. Cancer Med. 2020;9(3):1044–57.

Article  PubMed  Google Scholar 

Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351(Pt 2):289–305.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.

Article  CAS  PubMed  Google Scholar 

Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.

Article  CAS  PubMed  Google Scholar 

Laurent-Puig P, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924–30.

Article  CAS  PubMed  Google Scholar 

De Roock W, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.

Article  PubMed  Google Scholar 

Loupakis F, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3).

Tejpar S, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.

Article  PubMed Central  Google Scholar 

Cremolini C, et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol. 2017;28(12):3009–14.

Article  CAS  PubMed  Google Scholar 

Yoshino T, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. J Clin Oncol. 2022;40(17):LBA1–LBA1.

Article  Google Scholar 

Watanabe J, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329(15):1271–1282. A large phase 3 randomized clinical trial of doublet chemotherapy plus panitumumab vs bevacizumab in RAS wild-type metastatic CRC, with the primary endpoint of overall survival in patients with left-sided primary tumor location. This is the first clinical trial of anti-EGFR antibody plus chemotherapy to include primary tumor location in primary endpoint.

Shitara K, et al. Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: a biomarker study of the phase III PARADIGM trial. J Clin Oncol. 2023;41(4_suppl):11–11.

Article  Google Scholar 

Raghav K, et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;3:1–13.

PubMed  Google Scholar 

Strickler JH, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496–508.

Article  CAS  PubMed  Google Scholar 

Sartore-Bianchi A, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46.

Article  CAS  PubMed  Google Scholar 

Meric-Bernstam F, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siena S, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–89.

Article  CAS  PubMed  Google Scholar 

Siena S, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol. 2023;41(16_suppl):3501–3501.

Article  Google Scholar 

Bekaii-Saab TS, et al. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress. J Clin Oncol. 2023;41(4_suppl):TPS261–TPS261.

Article  Google Scholar 

Douillard JY, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7.

Article  CAS  PubMed  Google Scholar 

de Gramont A, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.

Article  PubMed  Google Scholar 

Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

Article  CAS  PubMed  Google Scholar 

Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.

Article  CAS  PubMed  Google Scholar 

Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.

Article